Evidence map›Paper›PMID 27136525›Full record

ArticleMolecules (Basel, Switzerland)2016

Photoactivatable Caged Prodrugs of VEGFR-2 Kinase Inhibitors.

Boris Pinchuk, Rebecca Horbert, Alexander Döbber, Lydia Kuhl, Christian Peifer

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. A Photocleavable Contrast Agent for Light-Responsive MRI.Pharmaceuticals (Basel, Switzerland) · 2020
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Boris PinchukInstitute of Pharmacy, University of Kiel, Gutenbergstr. 76, D-24118 Kiel, Germany. bpinchuk@pharmazie.uni-kiel.de.
Rebecca HorbertInstitute of Pharmacy, University of Kiel, Gutenbergstr. 76, D-24118 Kiel, Germany. rhorbert@pharmazie.uni-kiel.de.
Alexander DöbberInstitute of Pharmacy, University of Kiel, Gutenbergstr. 76, D-24118 Kiel, Germany. adoebber@pharmazie.uni-kiel.de.
Lydia KuhlInstitute of Pharmacy, University of Kiel, Gutenbergstr. 76, D-24118 Kiel, Germany. lkuhl@pharmazie.uni-kiel.de.
Christian PeiferInstitute of Pharmacy, University of Kiel, Gutenbergstr. 76, D-24118 Kiel, Germany. cpeifer@pharmazie.uni-kiel.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we report on the design, synthesis, photokinetic properties and in vitro evaluation of photoactivatable caged prodrugs for the receptor tyrosine kinase VEGFR-2. Highly potent VEGFR-2 inhibitors 1 and 3 were caged by introduction of a photoremovable protecting group (PPG) to yield the caged prodrugs 4 and 5. As expected, enzymatic and cellular proliferation assays showed dramatically diminished efficacy of caged prodrugs in vitro. Upon ultraviolet (UV) irradiation of the prodrugs original inhibitory activity was completely restored and even distinctly reinforced, as was the case for the prodrug 4. The presented results are a further evidence for caging technique being an interesting approach in the protein kinase field. It could enable spatial and temporal control for the inhibition of VEGFR-2. The described photoactivatable prodrugs might be highly useful as biological probes for studying the VEGFR-2 signal transduction.

Indexed as

ProdrugsCell LineCell ProliferationDrug DesignMolecular StructurePhotochemical ProcessesUltraviolet RaysVascular Endothelial Growth Factor Receptor-2ProdrugsVascular Endothelial Growth Factor Receptor-23,4-diarylmaleimidescagingkinase inhibitorsphotoactivatable prodrugsphotoremovable protecting group (PPG)receptor tyrosine kinaseVEGFR-2

Identifiers

PMID27136525
PMCPMC6274539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.